Our Technologies


48-49 Russell Square, London, WC1B 4JP UK

T: +44 (0)203 0084416

E: info@valirx.com

Our Technologies

In June 2009, Valirx, as the leading partner of an international consortium of three companies, was awarded a two year grant by Eurostar against substantial competition from across Europe, to develop its GeneICE technology (“GeneICE” or “Gene inactivation by chromatin engineering”), in which “rebellious genes”, which cause problems such as cancer and potentially some neurological problems, are shut down or “put on ice”.

The Eurostars programme is a EU grant scheme and EUrEKa Network initiative, created with the purpose of providing funding for market-oriented research and development activities by Small and Medium-sized Enterprises within the EU.

Valirx successfully led the funding application with GenoSyst (Finland) and PentaBase (Denmark) under the 2nd call to the Eurostars joint Programme, for design optimisation, lead selection and pre-clinical testing of GeneICE. The application was rated second in the UK and Finland and first in Denmark, coming in 4th overall out of over 500 applicants within the EU wide scheme.

The technology is under license from Imperial College, University of London and it has been shown to be effective against several cancer cell lines, including prostate cancer, ovarian cancer, pancreatic cancer and lung cancer. Valirx retains all commercial rights for GeneICE from the programme.

scientifist test tube